Nicox reported net revenue of 5.2 million euros in the second quarter of 2019 compared with net revenue of 0.2 million euros in 2018’s second quarter, according to a press release.
The company had cash and cash equivalents of 17.3 million euros as of June 30, which does not include an upfront payment of 2 million euros from Ocumension or a milestone payment of $3 million from Eyevance received in July.
Operational highlights for the quarter include a 17% increase in prescriptions for Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) compared (Read more...)
Uncategorized